Legal Representation
Attorney
Albert P. Halluin
USPTO Deadlines
Application History
32 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Oct 27, 2008 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Oct 27, 2008 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
Apr 4, 2008 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
Mar 14, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Mar 14, 2008 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
Sep 26, 2007 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
Sep 13, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Sep 13, 2007 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
Jun 28, 2007 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
Mar 20, 2007 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Mar 20, 2007 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
Oct 24, 2006 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Sep 22, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Sep 22, 2006 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Apr 28, 2006 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Mar 24, 2006 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Mar 24, 2006 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Sep 27, 2005 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Jul 5, 2005 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Jun 15, 2005 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
Mar 28, 2005 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
Mar 25, 2005 | ALIE | A | ASSIGNED TO LIE | Loading... |
Mar 18, 2005 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Mar 17, 2005 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED | Loading... |
Jan 31, 2005 | I | PAPER RECEIVED | Loading... | |
Jan 31, 2005 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Oct 5, 2004 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Aug 21, 2004 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Aug 12, 2004 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jul 20, 2004 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
Jul 16, 2004 | I | PAPER RECEIVED | Loading... | |
Feb 2, 2004 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
PHARMACEUTICALS